Remove Insulin Remove Marketing Remove Pharma Companies
article thumbnail

California’s low-cost insulin plans receive $100m manufacturing boost

Pharmaceutical Technology

Insulin prices made the headlines again as California governor Gavin Newsom announced plans on 7 July for the state to manufacture low-cost insulin. The state plans to work directly with a contract manufacturing organization (CMO) to manufacture low-cost insulin. In-house manufacturing the norm.

Insulin 328
article thumbnail

Insulin prices demonstrate pharma’s greed

World of DTC Marketing

WHAT’S HAPPENING: In the Build Back Better bill , Democrats are actually proposing limiting insulin prices to $35 a month but Republicans can’t have any of that. PhRMA spent pharma’s money well and bought some politicians while people who need insulin are suffering.

Insulin 184
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How the patient voice is becoming vital for drug approval

pharmaphorum

Rebecca Sanders from Lipodystrophy UK tells us how the patient voice helped convince NICE to approve a much-needed drug for this rare disease, and explores how regulators and pharma companies can help make patient involvement in HTA more impactful. This article appears in our free digital magazine Deep Dive: Market Access 2021.

Drugs 105
article thumbnail

Arecor heads for London Stock Exchange with drug reformulation strategy

pharmaphorum

Arecor Therapeutics is planning to float on the London stock market, to raise funding and awareness for its developmental portfolio of biologic drugs, which are based on already-marketed drugs reformulated to provide extra benefits for patients. .

Insulin 52
article thumbnail

Novo Nordisk: Prevention, digital tools and collaboration to define the future of diabetes

pharmaphorum

In our latest UK Leaders article Pinder Sahota, UK general manager at Novo Nordisk, tells us how he hopes to bring the NHS and pharma together to improve outcomes in diabetes and other long-term conditions. This will also mean the industry needs to think about how HCPs will want to interact with pharma companies. “If

article thumbnail

FDA head Califf on tighter accelerated approvals and lower drug prices at JP Morgan

Pharmaceutical Technology

While insulin price caps will begin this year, larger effects will be delayed until 2026 – when the US federal government will be allowed to negotiate Medicare prices and demand rebates from drug companies that price gouge. That leaves three years for pharma companies to prepare.

Drugs 130
article thumbnail

Elon Musk, pharma, and the future of Twitter

pharmaphorum

Musk’s arrival at the social platform has raised questions for users, which includes pharma companies who use Twitter for marketing and patients who utilise it to engage with their medical communities. The post Elon Musk, pharma, and the future of Twitter appeared first on. How to react.